Sequential high-dose therapy plus rituximab as in vivo purging agent in low grade lymphomas

被引：0
|
作者：
Mazza, P
Prudenzano, A
Pricolo, G
Stani, L
Maggi, A
Amurri, B
Palazzo, G
Pisapia, G
机构：
来源：
BONE MARROW TRANSPLANTATION | 2003年 / 31卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
下载
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [41] ONDANSETRON PLUS DEXAMETHASONE - AN EFFECTIVE COMBINATION IN HIGH-DOSE CISPLATIN THERAPY
    TONATO, M
    EUROPEAN JOURNAL OF CANCER, 1991, 27 : S12 - S14
  • [42] Sequential high-dose chemotherapy plus autograft in refractory Hodgkin's disease patients
    Karanfilski, O
    Stojanovic, A
    Cevreska, L
    Pivkova, A
    Stojanoski, Z
    Trajkova, S
    Krstevska-Balkanov, S
    Georgievski, B
    BONE MARROW TRANSPLANTATION, 2005, 35 : S386 - S387
  • [43] CHEMOTHERAPY OF INTERMEDIATE-GRADE AND HIGH-GRADE NON-HODGKINS LYMPHOMAS WITH A HIGH-DOSE DOXORUBICIN-CONTAINING REGIMEN
    ZUCKERMAN, KS
    LOBUGLIO, AF
    REEVES, JA
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (02) : 248 - 256
  • [44] HIGH-DOSE ALKYLATING AGENT THERAPY - A REVIEW OF CLINICAL-EXPERIENCES
    CORNBLEET, MA
    LEONARD, RCF
    SMYTH, JF
    CANCER DRUG DELIVERY, 1984, 1 (03): : 227 - 238
  • [45] Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial
    Furuta, Shunsuke
    Sugiyama, Takao
    Umibe, Takeshi
    Kaneko, Yuko
    Amano, Koichi
    Kurasawa, Kazuhiro
    Nakaomi, Daiki
    Hiraguri, Masaki
    Hanaoka, Hideki
    Sato, Yasunori
    Ikeda, Kei
    Nakajima, Hiroshi
    BMJ OPEN, 2017, 7 (12):
  • [46] Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC plus /-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas
    Tessoulin, B.
    Thomare, P.
    Delande, E.
    Moynard, J.
    Gastinne, T.
    Moreau, A.
    Bossard, C.
    Mahe, B.
    Blin, N.
    Dubruille, V.
    Touzeau, C.
    Boudreault, J. S.
    Perrin, F.
    Lok, A.
    Guillaume, T.
    Garnier, A.
    Peterlin, P.
    Gallas, P.
    Chevallier, P.
    Moreau, P.
    Le Gouill, Steven
    ANNALS OF HEMATOLOGY, 2017, 96 (06) : 943 - 950
  • [47] The role of radiotherapy for the development of secondary myeloid malignancies after high-dose therapy of lymphomas
    Belka, C
    STRAHLENTHERAPIE UND ONKOLOGIE, 2001, 177 (03) : 165 - 166
  • [48] In vivo purging with high dose cytarabine followed by high-dose therapy and reinfusion of unpurged peripheral stem cells for myelodysplasia or secondary acute myelogenous leukemia in first complete remission.
    Fung, HC
    Stein, A
    Spielberger, R
    Sniecinski, I
    Woo, D
    Bhatia, R
    O'Donnell, M
    Forman, SJ
    BLOOD, 1999, 94 (10) : 308A - 308A
  • [49] Initial high-dose sequential chemotherapy in the treatment of aggressive non-Hodgkin lymphomas with risk factors
    Welt, A
    Anhuf, J
    Krawczyk, C
    Fossa, A
    Stuschke, M
    Kloke, O
    Schütte, J
    Westerhausen, M
    Sack, H
    Seeber, S
    Nowrousian, MR
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 237 - 237
  • [50] Effect of rituximab and/or high-dose therapy with autotransolant at time of relapse in patients with follicular lymphoma
    Coiffier, Bertrand
    Brice, Pauline
    Delarue, Richard
    Haioun, Corinne
    Souleau, Bertrand
    Mounier, Nicolas
    Feugier, Pierre
    Tilly, Herve
    Sebban, Catherine
    BLOOD, 2007, 110 (11) : 120A - 120A
12345